Article Listing - US Bioscience Signs Euro Marketing Deal
Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
23 May 2013
Results of the INTERVAL study were published on line in The Lancet today (May 23) and for the first time demonstrated the feasibility of setting and achieving individualized treatment targets in elderly patients with type 2 diabetes.
Alexza deal with Teva sets stage for Adasuve, say analysts
23 May 2013
USA-based Alexza Pharmaceuticals' (Nasdaq: ALXA) US marketing deal with Israel-headquartered Teva Pharmaceutical Industries (NYSE: TEVA) for Adasuve (orally-inhaled Staccato loxapine; The Pharma Letter May 9) enhances the product's US sales prospects given Teva's expertise in the psychiatric and hospital markets, say analysts at Edison Investment Research.
Exec appointments at Biogen Idec and Halozyme; Succession plan for Forest Labs
23 May 2013
US biotech firm Biogen Idec (Nasdaq: BIIB) announced that Spyros Artavanis-Tsakonas, has been named chief scientific officer. Dr Artavanis-Tsakonas had served as interim CSO while on sabbatical from Harvard Medical School.
Positive clinical results for Zensun's Neucardin CHF patients
23 May 2013
USA and China-based Zensun Science & Technology has revealed positive results of four completed Phase II clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the US Phase II trial for Zensun's innovative "first-in-class" anti-heart failure drug, Neucardin, which has just been licensed to the USA's SciClone Pharmaceuticals (Nasdaq: SCLN) for Greater China (The Pharma Letter May 20).
Health care reforms not keeping pace with needs of Canadians, says report
23 May 2013
The Health Council of Canada today (May 23) released Progress Report 2013: Health care renewal in Canada, highlighting the progress achieved by governments in five key areas: wait times, primary health care and electronic health records, pharmaceuticals management, disease prevention/health promotion and Aboriginal health. The report finds that, overall, efforts at reform are not keeping pace with the changing health care needs of Canadians. There is variability of access to services across the country.
Netherlands first to approve Astellas' Vesomni
23 May 2013
The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) says that the Dutch Medicines Evaluation Board (MEB) has granted marketing authorization for Vesomni in the Netherlands, the first clearance for the drug, for treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men who are not adequately responding to treatment with monotherapy.
Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
23 May 2013
Australian drug developer Alchemia (ASX: ACL) and Merck Serono, a subsidiary of Germany's Merck KGaA (MRK: DE) have agreed to collaborate by supporting the initiation of a new clinical trial of HA-Irinotecan which will be conducted by principal investigator associate Professor Peter Gibbs. Financial terms were not disclosed.
Is the diabetes market facing a blockbuster-free future?
23 May 2013
Japanese drug major Takeda's (TYO: 4502) recently announced positive late-stage results for new type 2 diabetes drug, fasiglifam, has prompted excitement within the industry and raised hopes of reviving Takeda's diabetes treatment business, following last year's patent expiration of hit product Actos (pioglitazone). But as drugs continue to improve without the addressing the biggest unmet needs of the current therapy landscape, an analyst with research and consulting firm GlobalData asks, are we entering an era without blockbuster diabetes drugs?
EMA makes key recommendations to tackle the issue of medication errors
23 May 2013
The European Medicines Agency yesterday issued six key recommendations to tackle the issue of medication errors causing harm in the European Union. These recommendations are described in the medication-errors workshop report, which is available on the Agency's web site.
US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
23 May 2013
The US Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee yesterday voted 13 to three to approve drug giant Merck & Co's (NYSE: MRK) investigational insomnia medicine suvorexant at doses of 15mg and 20mg, but voted eight to seven (with one abstention) against the 30mg and 40mg doses, saying that these were not safe.
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
